Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels
Alcoholism Clinical and Experimental Research2016Vol. 41(1), pp. 179–186
Citations Over TimeTop 1% of 2016 papers
Katie Witkiewitz, Kevin A. Hallgren, Henry R. Kranzler, Karl Mann, Deborah S. Hasin, Daniel E. Falk, Raye Z. Litten, Stephanie S. O’Malley, Raymond F. Anton
Abstract
Changes in WHO risk levels appear to be a valid end point for alcohol clinical trials. Based on the current findings, reductions in WHO risk drinking levels during treatment reflect meaningful reductions in alcohol-related consequences and improved functioning.
Related Papers
- → Naltrexone and Nalmefene: Any Meaningful Difference?(2013)31 cited
- → Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder(2017)21 cited
- → Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study(2017)15 cited
- → Nalmefene against alcohol use disorder: A report of one case(2017)
- → Naltrexone and nalmefene efficacy in the treatment of gambling disorder with comorbid alcohol use disorder(2016)